Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Werewolf Therapeutics is currently pursuing a merger with Ambros and a concurrent PIPE financing to address substantial doubt about its ability to continue as a going concern. As of November 9, 2026, the company had 48,599,066 shares of common stock outstanding and is evaluating strategies to raise additional capital to fund its research and development programs.
Inhibrx Biosciences reported Q3 2026 financial results, highlighting a cash position of $199.5 million and $2.0 million in revenue from a licensing agreement with Pfizer. The company is advancing its clinical pipeline, with upcoming data presentations for ozekibart in Ewing sarcoma and ongoing enrollment in the Phase 2 HexAgon study for ordastobart.
Republic Digital Acquisition Company is a special purpose acquisition company (SPAC) that reported 30,000,000 Class A and 7,500,000 Class B ordinary shares outstanding as of November 13, 2026. The company's cash position decreased from $1,016,713 at the end of 2025 to $643,377 as of September 30, 2026, as it continues to seek an initial business combination within its designated 24-month period.
For the nine months ended September 30, 2026, Royalty Management Holding Corp reported total revenue of $5.63 million, a significant increase from $3.55 million in the prior year, primarily driven by environmental services. Despite the revenue growth, the company realized a net loss of $257,687 for the period, though this was an improvement over the $317,131 net loss reported in the same period of 2025.
Adaptin Bio, Inc. reported a net loss of $3.31 million for the nine months ended September 30, 2026, compared to a $3.80 million loss in the prior year period. The company remains in the development stage with no revenue, maintaining a stockholders' deficit of $1.67 million and a cash balance of $430,333 as of the reporting date.
Digimarc reported a total revenue of $6.4 million for the third quarter of 2026, a decrease from $7.6 million in the prior year, primarily driven by lower subscription revenue. The company's net loss narrowed slightly to $7.9 million for the quarter, while cash and cash equivalents increased to $20.7 million as of September 30, 2026.
EnerSyn Global Inc. reported a significant increase in total assets to $17.8 million as of September 30, 2026, driven by a substantial cash infusion and common stock issuances. However, the company experienced a widened net loss of $3.4 million for the nine months ended September 30, 2026, primarily due to a sharp rise in general and administrative expenses.
Rocket One Inc. reported a total asset increase to $8.66 million as of September 30, 2026, driven by new intangible assets and goodwill, despite a decrease in cash and cash equivalents. The company's accumulated deficit grew to $82.09 million, reflecting ongoing operational losses during its strategic repositioning into orbital and defense technologies.
MEDO Technologies, Inc. reported a net loss of $191,301 for the three months ended September 30, 2026, and a cumulative net loss of $400,884 for the nine-month period. The company remains in a deficit position with total stockholders' deficit of $395,563 and implemented a 1-for-100,000 reverse stock split effective September 23, 2026.
Columbus Circle Capital Corp III is a shell company that completed its IPO on July 10, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company has 23,665,000 Class A and 7,666,667 Class B ordinary shares outstanding and is seeking a business combination within a 24-month period.
SmartKem, Inc. reported a net loss of $24.1 million for the nine months ended September 30, 2026, significantly impacted by a $45.6 million loss on the write-off of bad debts and $11.9 million in ELOC commitment share expenses. Despite these losses, the company improved its balance sheet through debt-to-equity conversions and preferred stock issuances, ending the period with $4.3 million in cash and total stockholders' equity of $12.8 million.
Our Bond, Inc. reported a significant increase in net loss to $16.1 million for the nine months ended September 30, 2026, compared to $7.8 million in the prior year, driven by a doubling of operating expenses. Revenue slightly declined to $6.98 million, while the company maintained a stockholders' deficit of $16.97 million.
CERo Therapeutics Holdings, Inc. is an emerging growth company focused on developing its lead product candidate, CER-1236. As of November 13, 2026, the company reported 83,309,742 shares of common stock outstanding and noted the impact of its delisting from Nasdaq as a significant risk factor.
For the nine months ended September 30, 2026, CIFC Direct Lending Evergreen Fund reported total investment income of $22.8 million and net investment income of $10.3 million. Total net assets grew to $112.1 million, supported by $11.0 million in net increase from operations and $9.0 million in capital contributions, partially offset by $9.9 million in distributions and redemptions.
OptimizeRx reported Q3 2026 revenue of $21.6 million, a 17% year-over-year decrease, while GAAP net income rose to $1.2 million. The company updated its full-year 2026 revenue guidance to $87-$93 million but maintained its adjusted EBITDA outlook. Management highlighted significant margin expansion and a reduction in debt principal to $10.4 million.
Term
Q3 2026
“Third quarter revenue and adjusted EBITDA both exceeded consensus expectations, reflecting continued margin expansion, disciplined execution, and the resilience of our operating model. While revenue declined year-over-year, adjusted EBITDA increased approximately 23%, with adjusted EBITDA margins expanding over 900 basis points, demonstrating the benefits of our improved product mix and cost management initiatives.”
Stephen L. Silvestro, OptimizeRx CEO
“While in-year contracted revenue continues to track below prior-year levels, resulting in a revision to our full-year 2026 revenue outlook, we remain encouraged by the growth we are seeing in contracted revenue for 2027, highlighting a start to a strong RFP season.”
For the nine months ended September 30, 2026, FB Bancorp reported net income of $515 thousand, a significant decrease from $2.66 million in the prior year period, primarily due to a $1.14 million loss from discontinued operations and increased non-interest expenses. Total assets decreased to $1.21 billion from $1.26 billion at year-end 2025, while stockholders' equity was impacted by $32.3 million in common stock repurchases.
Yorkville International Capital Corp. is a special purpose acquisition company (SPAC) that completed its IPO on June 17, 2026, raising $230 million held in a trust account. As of September 30, 2026, the company is in its search phase for an initial business combination and reported 23,000,000 Class A and 15,333,333 Class B ordinary shares outstanding.
TRG Latin America Acquisitions Corp. is a special purpose acquisition company (SPAC) that completed its IPO on February 27, 2026, raising proceeds for a trust account totaling $210,677,645 as of September 30, 2026. The company is currently in its combination period with a deadline of February 27, 2028, to consummate an initial business combination.
Pony Group Inc. reported a net loss of $147,554 for the nine months ended September 30, 2026, compared to a loss of $115,100 in the prior year period. Total revenue decreased slightly to $97,880 from $104,137, while the company continues to operate with a significant stockholders' deficit of $1,100,109.
Owlet, Inc. reported 29,889,307 shares of Class A Common Stock outstanding as of November 9, 2026. The filing highlights significant risks including a history of losses, reliance on single manufacturers for key products like Dream Sock and Owlet Cam, and a recent camera cable guard safety update and stop sale initiated in November 2026.
Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.
Term
Q3 2026
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
TherapeuticsMD reported third quarter 2026 financial results, highlighting license revenue of $1.3 million, a 60.6% increase year-over-year. The company achieved a $0.5 million net income from continuing operations and ended the period with $10.4 million in cash. Management noted the achievement of a sales-based milestone for IMVEXXY and continues to evaluate strategic alternatives including potential mergers or asset sales.
Espey Mfg. & Electronics Corp. reported net sales of $10.6 million for the quarter ended September 30, 2026, a 16.7% increase over the prior year. Despite higher sales, net income remained relatively flat at $2.19 million due to increased cost of sales and lower interest income.
BullFrog AI Holdings, Inc. reported a net loss of $4,976,572 for the nine months ended September 30, 2026, compared to a loss of $5,017,894 in the prior year period. While collaboration revenue increased to $278,963, the company continues to incur significant operating expenses primarily driven by general and administrative costs and research and development.
OptimumBank Holdings, Inc. reported a significant increase in net income to $18.5 million for the nine months ended September 30, 2026, compared to $11.8 million in the prior year. Total assets grew to $1.58 billion, driven by a substantial increase in the loan portfolio and the issuance of $34.4 million in subordinated debt.
Skye Bioscience reported a significant decrease in cash and short-term investments from $25.7 million at year-end 2025 to $4.8 million as of September 30, 2026. The company experienced a net loss of $23.2 million for the first nine months of 2026, driven primarily by $13.2 million in research and development expenses. A 1-for-8 reverse stock split was effected on August 24, 2026.
National Presto Industries reported a significant increase in net earnings for the nine months ended October 4, 2026, reaching $42.5 million compared to $18.1 million in the prior year period. This growth was driven by a 20.6% increase in net sales to $409.6 million and improved gross profit margins, alongside a $1.7 million gain from the sale of property, plant, and equipment.
AB Private Lending Fund reported a net increase in net assets resulting from operations of $8.86 million for the nine months ended September 30, 2026, compared to $9.22 million in the prior year period. Total investment income grew to $25.86 million, though net investment income per share decreased from $1.86 to $1.69 due to a higher weighted average share count.
First National Corp reported net income of $1.25 per share for both the third quarter and the first nine months of 2026. The company maintained stable dividend payouts and saw a slight increase in total assets compared to the prior year-end, supported by growth in interest and fees on loans.
Enveric Biosciences reported financial results for the third quarter of 2026 and provided a corporate update on its lead candidate EB-003. The company is completing final IND-enabling activities for EB-003, a non-hallucinogenic neuroplastogenic candidate, with plans for an IND submission and Phase 1 clinical trial.
Term
Q3 2026
“Our focus during the third quarter was advancing final IND-enabling activities for EB-003 as we prepare for the planned IND submission and first-in-human Phase 1 clinical trial of our lead non-hallucinogenic, neuroplastogenic candidate.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric
“The growing body of preclinical evidence reinforces our confidence in this opportunity as we complete the final IND-enabling activities and prepare to advance EB-003 toward first-in-human clinical development.”
Joseph Tucker, Ph.D., Chief Executive Officer of Enveric